NASDAQ · BGMS
Healthcare · Medical - Pharmaceuticals
$0.90
Up+$0.02 (+2.65%)
Updated Nov 5, 2026, 1:45 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BGMS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
BGMS closed at $0.90 after 21 trading sessions, up 5.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $0.872 | $0.9099 | $0.8708 | $0.8951 | 9.64K |
| Nov 3, 2026 | $0.89 | $0.90 | $0.84 | $0.872 | 26.88K |
| Nov 2, 2026 | $0.9247 | $0.9247 | $0.90 | $0.90 | 10.57K |
| Oct 30, 2026 | $0.90 | $0.92 | $0.90 | $0.90 | 11.53K |
| Oct 29, 2026 | $0.9338 | $0.9774 | $0.83 | $0.83 | 20.25K |
| Oct 28, 2026 | $0.9143 | $0.9201 | $0.9067 | $0.9201 | 4.32K |
| Oct 27, 2026 | $0.9312 | $0.9436 | $0.9312 | $0.9436 | 2.8K |
| Oct 26, 2026 | $0.9298 | $0.9748 | $0.9298 | $0.9524 | 6.11K |
| Oct 23, 2026 | $0.905 | $0.9884 | $0.8716 | $0.96 | 23.82K |
| Oct 22, 2026 | $0.97 | $0.97 | $0.92 | $0.9438 | 10.24K |
| Oct 21, 2026 | $0.92 | $1.01 | $0.8832 | $1.00 | 52.98K |
| Oct 20, 2026 | $0.94 | $0.9994 | $0.94 | $0.94 | 51.53K |
| Oct 19, 2026 | $0.87 | $0.9696 | $0.86 | $0.9329 | 46.09K |
| Oct 16, 2026 | $0.835 | $0.9186 | $0.835 | $0.9093 | 30.73K |
| Oct 15, 2026 | $0.8505 | $0.8662 | $0.8201 | $0.8327 | 15.08K |
| Oct 14, 2026 | $0.91 | $0.9101 | $0.8568 | $0.8945 | 17.43K |
| Oct 13, 2026 | $0.978 | $0.978 | $0.89 | $0.9199 | 50.49K |
| Oct 12, 2026 | $0.869 | $1.08 | $0.8525 | $0.99 | 277.4K |
| Oct 9, 2026 | $0.80 | $0.85 | $0.80 | $0.849 | 23.85K |
| Oct 8, 2026 | $0.8408 | $0.8928 | $0.81 | $0.821 | 16.98K |
| Oct 7, 2026 | $0.8557 | $0.8719 | $0.849 | $0.85 | 5.91K |
The latest Smart Investors Daily articles mentioning BGMS.
Company
Market Activity
Research & News
BGMS research
Company profile and research snapshot.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Oct 29, 2026
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million. CareDx (NASDAQ:CDNA) stock rose 15.0% to $82.25.
Benzinga · Oct 19, 2026
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX) shares moved
Benzinga · Sep 14, 2026
Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose 10.65% to
Yahoo · Sep 10, 2026
~ Transaction values Firstborn Top Capital at pro forma enterprise value of approximately $1,091.2 million ~~ Firstborn Top Capital is a licensed private financing company committed to providing responsible, transparent and accessible financial solutions to individuals and businesses across Malaysia ~~ Executive Director, Ow Ruey Shen, will continue to lead Firstborn Top Capital ~~ Transaction provides Firstborn Top Capital the capital to accelerate growth throughout Malaysia, then Southeast Asi
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BGMS.
No results
No recent SID articles mention BGMS.
